Latest news with #2024UniversalRegistrationDocument
Yahoo
2 days ago
- Business
- Yahoo
Renewal of the drawdown under the Revolving Credit Facility for a six-month period
Press release 4 June 2025Renewal of the drawdown under the Revolving Credit Facility for a six-month periodParis, 4 June 2025 - Clariane ( - ISIN FR0010386334) announces that it has renewed the drawdown of its RCF (Revolving Credit Facility) for a period of 6 months for an amount of €490.8 million, in accordance with the terms of the contract signed February 14th, addition to the usual conditions, the Group points out that the drawdown and renewal of its RCF line are subject to a minimum liquidity level of €300 million on the day of the drawdown or renewal, which includes the RCF drawn down. This document contains forward-looking statements that involve risks and uncertainties, including those included or incorporated by reference, concerning the Group's future growth and profitability that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements made in this document constitute expectations for the future and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the 2024 Universal Registration Document filed with the AMF on 1 April 2025 under registration number D.25-0209, available on the Company's website ( and that of the AMF ( All forward-looking statements included in this document are valid only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond the requirements of applicable are cautioned not to place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accepts any responsibility for the reasonableness of any assumptions or opinions expressed or for the likelihood of any projections, prospects or performance being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be construed as a promise or representation regarding the future. Furthermore, nothing contained in this document is intended to be or should be construed as a forecast of results. Clariane's past performance should not be taken as a guide to future performance. The main Alternative Performance Indicators (APIs), such as EBITDA, EBIT, net debt and financial leverage, are defined in the Universal Registration Document available on the Company's website at ClarianeClariane is the leading European community of care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands and Spain. Relying on their diverse expertise, each year, the Group's 60,000 professionals provide services to 900,000 patients and residents in three main areas of activity: care homes (Korian, Seniors Residencias, etc.), healthcare facilities and services (Inicea, Ita, Grupo 5, etc.), and alternative living solutions (Petits-fils, Ages & Vie, etc.). In June 2023, Clariane became a purpose-driven company and added to its bylaws a new corporate purpose, common to all its activities: 'taking care of each person's humanity in times of vulnerability'.Clariane has been listed on Euronext Paris, Section B since November 2006. The Group joined the SBF 120 index and the CAC® SBT 1.5° index on 23 September ticker: - ISIN: Bisseuil Benoît Lesieur Head of Investor Relations Deputy Head of Investor Relations – ESG +33 6 58 60 68 69 +33 6 64 80 15 90 Julie Mary Florian Bachelet Press officer Press officer +33 6 59 72 50 69 +33 6 79 86 78 23 Attachment Press Release Clariane-renewal of drawdown under the RCFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Planisware - Availability of documents relating to the general meeting
Availability of documents relating to the combined general meeting of June, 19 2025 Paris, France, May 27, 2025 – Shareholders of Planisware, a leading B2B provider of SaaS in the rapidly growing Project Economy, are invited to attend the Annual General Meeting to be held on Thursday, June 19, 2025 at 9am CET. at Planisware's headquarters, 200, avenue de Paris - 92320 Châtillon, France (the 'Meeting'). The meeting notice, including the agenda and the text of the proposed resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) No. 57 on May 12, 2025. The procedures for participating and voting at this Meeting are set out in this notice. It will be followed by a convening notice published in the BALO and in a legal gazette within the time limits specified by applicable laws and regulations. These notices are also available on Planisware website at the following address: (section 2025 General Meeting). The Meeting will be broadcasted live on Planisware website1. How to participate Shareholders may choose one of the following three methods to exercise their voting rights at the Meeting: attend the Meeting; proxy the Chairman of the Meeting or any other natural or legal person; vote by mail or online on the VOTACCESS website. The terms and conditions for participation will be detailed in the convening notice, which will be posted on the Planisware website (section General Meeting 2025). Availability of preparatory documents Shareholders may from now on consult and download the information and documents provided for in Article R.22-10-23 of the French Commercial Code (including the meeting notice, the convocation brochure, and the 2024 Universal Registration Document) relating to the Meeting on the Planisware's website at the following address: (section 2025 General Meeting). Documents that must be made available to shareholders in connection with general meetings are available at Planisware's registered office, located at 200, avenue de Paris - 92320 Châtillon, France, in accordance with applicable legal and regulatory provisions. Written questions from shareholders Shareholders may submit written questions to Planisware in accordance with Articles L. 225-108 and R. 225-84 of the French Commercial Code. These questions should preferably be sent by email to the following address: assembleegenerale@ (or to Planisware's registered office by registered letter with acknowledgment of receipt) no later than the fourth business day prior to the date of the Meeting, i.e., by midnight on June 13, 2025. They must be accompanied by proof of registration in the account. Upcoming event June 24, 2025: Dividend Ex-date June 26, 2025: Dividend Pay-date July 31, 2025: H1 2025 results publication October 21, 2025: Q3 2025 revenue publication Contact Investor Relations Media Benoit d'Amécourt Brunswick GroupHugues Boëton / Tristan Roquet Montégon planisware@ +33 6 75 51 41 47 +33 6 79 99 27 15 / +33 6 37 00 52 57 About Planisware Planisware is a leading business-to-business ('B2B') provider of Software-as-a-Service ('SaaS') in the rapidly growing Project Economy. Planisware's mission is to provide solutions that help organizations transform how they strategize, plan and deliver their projects, project portfolios, programs and products. With circa 750 employees across 16 offices, Planisware operates at significant scale serving around 600 organizational clients in a wide range of verticals and functions across more than 30 countries worldwide. Planisware's clients include large international companies, medium-sized businesses and public sector entities. Planisware is listed on the regulated market of Euronext Paris (Compartment A, ISIN code FR001400PFU4, ticker symbol 'PLNW'). For more information, visit: and connect with Planisware on LinkedIn. 1 Unless technical reasons make this impossible or seriously disrupt the broadcast. Furthermore, it is noted that live voting via the Internet will not be possible during the broadcast of the Meeting. Attachment Planisware - Availability of documents relating to the general meeting - PRSign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
FDJ UNITED: Combined General Meeting of 22 May 2025
BOULOGNE, France, May 23, 2025--(BUSINESS WIRE)--Regulatory News: The annual and extraordinary Ordinary General Meeting of La Française des Jeux (Paris:FDJ) was held this Thursday, 22 May, under the chairmanship of Stéphane Pallez, Chairwoman and CEO. Shareholders were able to cast their votes during the General Meeting on presentation of an admission card. Shareholders who were unable to physically attend the meeting were able to vote by post, by proxy or via the secure Votaccess platform prior to the General Meeting. The General Meeting largely adopted all the resolutions put to the vote of the shareholders, including: - The approval of the parent company and consolidated financial statements for the 2024 financial year;- The appropriation of earnings for the financial year ended 31 December 2024 and the payment of a dividend of €2.05 per share to be paid on 3 June 2025;- The appointment of Ms Alix Boulnois as director;- The components of remuneration of the corporate directors for the 2024 financial year, as well as the 2025 remuneration policy for corporate directors;- Various financial authorisations granted to the Board of Directors;- Various amendments to the Articles of Association in order to incorporate the new purpose of FDJ UNITED in the preamble. In 2026, the General Meeting will be held on 23 April. Continuation of the liquidity agreement – Implementation of the share buyback programme Today's General Meeting adopted, in its 11th resolution, a new share buyback programme. A description of this programme can be found in the 2024 Universal Registration Document (chapter 7.2.2.1) filed on 29 April 2025 with the AMF and available on the FDJ website ( On 15 April 2025, the Board of Directors decided, subject to the condition precedent of the adoption of the 11th resolution of the General Meeting, to implement this programme in order to continue the liquidity agreement entered into with Exane. Resignation of Mrs Barjou - Director Following Predica's withdrawal from FDJ UNITED, Florence Barjou has tendered her resignation. The Chairman and CEO thanks her for her commitment and contribution to the Board of Directors of FDJ UNITED since March 1, 2022. About FDJ UNITED FDJ UNITED is one of Europe's leading betting and gaming operators, with a vast portfolio of iconic brands and a reputation for technological excellence. With more than 5,000 employees and a presence in around fifteen regulated markets, the Group offers a diversified, responsible range of games, both under exclusive rights and open to competition: lottery games in France and Ireland, via an extensive point-of-sale network and online; sports betting at points of sale in France; and online games open to competition (sports and horse-race betting, poker and online casino games, in markets where these activities are authorized). FDJ Group has placed responsibility at the heart of its strategy and promotes recreational betting. FDJ Group is listed on the Euronext Paris regulated market (FDJU) and is a member of indices including the SBF 120, Euronext 100, Euronext Vigeo 20, EN EZ ESG L 80, STOXX Europe 600, MSCI Europe and FTSE Euro. For more information, visit X @FDJUNITED Instagram @FDJUNITED_officiel LinkedIn @FDJUNITED View source version on Contacts Media +33 (0)1 41 10 33 82 | media@ Investor Relations+33 (0)1 41 04 19 74 | invest@
